Apax Partners has decided not to go forward with plans to form a continuation fund for some of its portfolio companies, Secondaries Investor has learned. London-headquartered Apax had been mulling a ...

Houlihan Lokey has hired a senior investment professional from Metlife Investment Management as it continues to grow its secondaries advisory team. Yugveer Singh, a director responsible for the ...

GP-led deal activity reached a new record last year and is expected to account for half of all secondaries transaction volume in the medium term, according to research from Greenhill. GP-led ...

Goldman Sachs Asset Management has held the final close on the fifth-largest secondaries fund ever raised. The firm has collected $10.3 billion for Vintage VIII, 20 percent of which has already been ...

The real estate secondaries market has undergone a fundamental shift, according to a report by CBRE Investment Management.

As refinancing pressures mount and exits remain elusive, real estate investors are turning to recapitalisations to unlock ...

The real estate secondaries market is entering a new phase of maturity, characterised by narrowing bid-ask spreads, improved ...

Cathay Life, historically one of Asia’s most active LPs, is offloading a portfolio of private equity stakes to HarbourVest Partners. The insurer has agreed to sell about $1.2 billion worth of stakes ...

Bridgepoint – the owner of Secondaries Investor’s parent company PEI Group – is the latest alternatives firm to expand into the secondaries market with the addition of Newbury Partners’ full team in a ...

ICG, manager of the market’s biggest platform dedicated to GP-led secondaries, has paused the launch of its planned mid-market strategy focusing on concentrated continuation fund bets. The ...

Private credit has become a significant segment of the secondaries market, with recent reports from Evercore and LGT Capital Partners placing 2025 volume at or above $20 billion. As demand for these ...

A HarbourVest Partners-backed single-asset deal involving a pharmaceutical company has generated significant returns for LPs who chose to part ways with their exposure to the prized asset.